Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

(2R,6R)-Hydroxynorketamine as a Novel Treatment for Opioid Use Disorder

Award Number: F31DA063341
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 08/15/2026
PERIOD OF PERFORMANCE END DATE: 08/14/2027

Group Awards By:

View Award Description

(2R,6R)-Hydroxynorketamine as a Novel Treatment for Opioid Use Disorder - Project Summary: Psychoplastogens have emerged as potential treatments for psychiatric disorders, including substance use disorders. For example, recent studies have shown that low-dose ketamine may be an effective treatment for depression and opioid use disorder (OUD). Despite promising results, the use of ketamine remains limited due to its side effects and misuse potential. More recently, researchers have turned to (2R,6R)-Hydroxynorketamine (HNK), a ketamine metabolite that has exhibited therapeutic effects in preclinical models of depression and stress, but unlike ketamine, HNK lacks misuse potential and dissociative properties. Our lab recently found that HNK reduces oxycodone withdrawal symptoms and reinstatement of oxycodone conditioned place preference. To build on these exciting data and make advancements towards potential treatments for OUD, I propose to use a combination of behavioral and cell type-specific approaches to investigate the behavioral effects and cellular mechanisms of HNK in multiple OUD models. In Aim 1, I will identify brain regions and specific cell-types involved in the therapeutic response of HNK during oxycodone withdrawal. In Aim 2, I will determine the effects of HNK on extinction and reinstatement of oxycodone self-administration. To achieve these goals, I will receive advanced training in behavioral pharmacology, sophisticated animal models of SUD, cell type-specific analysis, and chemogenetics. Overall, this proposal will provide critical insights into the neural mechanisms underlying the therapeutic effects of HNK in opioid withdrawal, highlighting its potential as a novel treatment for OUD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $48,660 )
2026	2026	UNIVERSITY OF CONNECTICUT	438 WHITNEY RD EXTENSION UNIT 1133	STORRS	CT	06269	CAPITOL	USA	Drug Use and Addiction Research Programs	001	1	3/25/2026	NEW	$576
2026	2026	UNIVERSITY OF CONNECTICUT	438 WHITNEY RD EXTENSION UNIT 1133	STORRS	CT	06269	CAPITOL	USA	Drug Use and Addiction Research Programs	000	1	2/16/2026	NEW	$48,084
														Subtotal = $48,660

Grand Total All Awards = $48,660

Top

All Categories

About

Search

Reports

Data Submission

Award Information

(2R,6R)-Hydroxynorketamine as a Novel Treatment for Opioid Use Disorder

Award Number: F31DA063341

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 08/15/2026

PERIOD OF PERFORMANCE END DATE: 08/14/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer